Introduction:
One of the key action areas of the World Health Organization third Global Patient Safety Challenge1 ‘Medication Without Harm’ (WHO, 2017) is to reduce severe avoidable medication-related harm and address polypharmacy. NICE guidance on falls risk assessment and prevention2 also includes medication review as part of its recommended multifactorial risk assessment (NICE, 2013). Use of Falls Risk Increasing Drugs3 (FRIDs) along with polypharmacy and anticholinergic burden are known to increase the risk of falls, particularly in older people2. In 2021, Belfast HSC Trust appointed a pharmacist to work with the community falls multidisciplinary team and optimise medicines in older people at risk of falls, and we aim to explore the impact of this role on medicines optimisation in older people.
Method:
This research quantitatively evaluates the impact of the intervention of a novel community falls pharmacist role on medicines optimisation, in relation to FRIDs in older people who have had a fall. We will present data on admission and discharge from the service in relation to:
- Number and type of FRIDs prescribed
- Calculation of Anticholinergic Burden score using the ACBcalc® (King and Rabino, 2022)
- Polypharmacy- number of medications prescribed
- The appropriateness of medicines prescribed
- Undertake measurement of lying/ standing manual blood pressure to identify potential postural drop in blood pressure, and hypertension.
- Undertake a Bone health review using an approved tool (FRAX)
- Outcome of pharmacist referral of appropriate patients for DEXA scan using a new direct referral system
- Measure the significance of clinical interventions (Eadon graded)
- Calculate the cost avoidance of pharmacist interventions (ScHARR Tool) Results
Results:
92 patients were reviewed by phone (35%) or during home visit (65%), by the community falls pharmacist June 2022- August 2023.
- FRIDs3 prescribed, were identified and reviewed, and Anticholinergic Burden score (ACB) was measured using the anticholinergic burden calculator4 (ACBcalc®)
- The number of medications prescribed and the appropriateness of these was measured using Medicines Appropriateness Index5 (MAI)
- Significance of clinical interventions by the community falls pharmacist was measured using Eadon6 scale and cost avoidance of these measured using an adapted version of the ScHARR tool7. Potential cost savings8 from deprescribing, and environmental impact were calculated (every £1 spent on pharmaceuticals generates greenhouse gas emissions 0.1558kg C029)
- Lying/ standing manual BP measurement was undertaken
- Bone health review was undertaken using a fracture risk assessment tool10 (FRAX®) & appropriate patients referred for a DEXA scan, using a new direct pharmacist referral pathway
Results indicate a medicines review by the community falls pharmacist leads to a statistically significant reduction in polypharmacy (¯8%; p<0.05) and ACB (¯33%; p<0.05), an increased appropriateness of prescribing (MAI ¯56%; p<0.05), 317 clinically significant interventions, identification of blood pressure issues (22%) eg orthostatic hypotension, and identification of osteopenia (n=14) or osteoporosis (n=3) using a new pharmacist DEXA referral pathway. Amitriptyline was the most common FRID deprescribed (22%). Annual cost avoidance due to pharmacist interventions were in the range of £28160 – £62358 along with drug cost savings of £6041, amounting to total savings of £34201-£68400, and invest to save return of one to two pounds for every £1 invested. Benefit to the environment of reduced inappropriate prescribing amounted to almost 1 tonne of avoidable CO2 emissions per year.
Discussion:
The pharmacist review had a statistically significant impact on reducing the ACB score by an average of 33% . The MAI pre- and post-review reduced by an average of 56% indicating an improvement in appropriateness of prescribing. 101 FRIDs were deprescribed & amitriptyline was deprescribed in 22% patients. 94% of clinical interventions were significant resulting in improvement in care and an additional 19 preventing potentially serious outcomes.
Conclusion:
Introduction of a community falls pharmacist role is an effective and cost efficient means to optimise medicines in older people who experience falls, as well as having a positive impact on the environment. The community falls pharmacist prescribing appropriateness, generates a return of £1-£2 per £1 invested, & ¯CO2 emissions by 1 tonne
1 World Health Organisation (WHO) Third Global Patient Safety Challenge: Medication Without Harm 2017 www.who.int
2 NICE Falls In Older People: Assessing risk and prevention Guidance 2013 www.nice.org.uk
3 Falls Risk Increasing Drugs (FRIDs): NI Medicines Optimisation Older People (MOOP) 2022
4 ACBcalc® ACB Calculator web app created by Dr Rebecca King and Steve Rabino
5 Hanlon, J. et al. A method for assessing drug therapy appropriateness, J Clin Epidemiol. 1992 45(10):1045-51
6 Eadon, H. Assessing the quality of ward pharmacists’ interventions. Int J Pharm Pract. 1992 1:3; 145-147
7 Miller, R. et al. Consultant pharmacist case management of older people in intermediate care. EJPCH 2016 4:1; 46-52
8 Health & Personal Social Services NI September 2023 Drug Tariff (hscni.net)
9 Gompertz, D. ‘Show me your meds, please’: the impact of home-based medicines assessments. The Pharmaceutical Journal 2023 vol 310. no. 7971;310
10 Fracture Risk Assessment Tool (FRAX®) University of Sheffield www.frax.shef.ac.uk